Basic and clinical studies of cefozopran in the urological field

We studied the antibacterial activity and clinical efficacy of cefozopran (CZOP), a new cephalosporin antibiotic, in the urological field. 1) Antibacterial activity : We measured MICs of CZOP against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime (CAZ), latamoxef, and cefoperazone. In general, the antibacterial activities of CZOP were almost equal to those of CAZ but superior to those of other control cephems, and slightly inferior to those of IPM. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 78.7 % (37/47) for chronic complicated UTI. Bacteriologically, 41 of 47 strains (87.2 %) were eradicated. As regards 2 cases of acute bacterial prostatitis, overall clinical efficacy was moderate and strains were eradicated in both cases. 3) Side effects: No clinical side effects were observed. Concerning laboratory findings, transient elevation of GOT and GPT were noted in two cases, eosinophilia in one case and a transient elevation of s-Cr in one case.